ArticleBMC psychiatry2022
An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample.
Article in BMC psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Substitution of Cannabis for Prescribed Medications in the Management of Anxiety and Depression Among Midlife Women: A Cross-Sectional Study.Health science reports · 2026Article
- Beyond cannabis use severity: associations of cannabis product type with sleep quality and mental health.Psychopharmacology · 2026Article
- Liquisolids as a platform for the formulation of cannabis tablets.International journal of pharmaceutics: X · 2026Article
- Joint Relations Among Cannabis, Sleep, and Affective Symptomatology: A Scoping Review.Current addiction reports · 2026Review
- Real-world quality of life and sleep outcomes in patients treated with THC- and CBD-richFrontiers in pharmacology · 2026Article
- Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and older.Scientific reports · 2025Article
- Cannabis use disorder risks among Medicaid enrollees with comorbid psychiatric illnesses: 2012-2021.Drug and alcohol dependence · 2025Article
- Full-spectrum cannabis extracts for women with chronic pain syndromes: a real-life retrospective report of multi-symptomatic benefits after treatment with individually tailored dosage schemes.Frontiers in pharmacology · 2025Article
- Using Cannabis and CBD to Sleep: An Updated Review.Current psychiatry reports · 2024Review
- Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials.International journal of molecular sciences · 2024Article
- Longitudinal associations between insomnia, cannabis use and stress among US veterans.Journal of sleep research · 2024Article
- Using Smartphone Technology to Track Real-Time Changes in Anxiety/Depression Symptomatology Among Florida Cannabis Users.Cannabis (Albuquerque, N.M.) · 2024Article
- Medical Cannabis Prescription Practices and Quality of Life in Thai Patients: A Nationwide Prospective Observational Cohort Study.Medical cannabis and cannabinoidsArticle
- Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review.Medical cannabis and cannabinoidsArticle
- Long-Term, Self-Dosing CBD Users: Indications, Dosage, and Self-Perceptions on General Health/Symptoms and Drug Use.Medical cannabis and cannabinoidsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about cannabis use for insomnia in individuals with depression, anxiety, and comorbid depression and anxiety. To develop a better understanding of distinct profiles of cannabis use for insomnia management, a retrospective cohort study was conducted on a large naturalistic sample.
methodsData were collected using the medicinal cannabis tracking app, Strainprint®, which allows users to monitor and track cannabis use for therapeutic purposes. The current study examined users managing insomnia symptoms in depression (n = 100), anxiety (n = 463), and comorbid depression and anxiety (n = 114), for a total of 8476 recorded sessions. Inferential analyses used linear mixed effects modeling to examine self-perceived improvement across demographic variables and cannabis product variables.
resultsOverall, cannabis was perceived to be efficacious across all groups, regardless of age and gender. Dried flower and oral oil were reported as the most used and most efficacious product forms. In the depression group, all strains were perceived to be efficacious and comparisons between strains revealed indica-dominant (M
conclusionsIn terms of perceptions, individuals with depression, anxiety, and both conditions who use cannabis for insomnia report significant improvements in symptom severity after cannabis use. The current study highlights the need for placebo-controlled trials investigating symptom improvement and the safety of cannabinoids for sleep in individuals with mood and anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.